Copyright
©2014 Baishideng Publishing Group Co.
Figure 1 Recurrence-free survival.
A: The 2-year recurrence-free survival (RFS) rate was 69.8%; B: The RFS curves stratified by pathological stage.
Figure 2 Overall survival.
A: The 2-year overall survival (OS) rate was 88.3%; B: The OS curves stratified by pathological stage.
- Citation: Uramoto H, Nakanishi R, Uchiyama A, Inoue M, Sugaya M, Iwata T, Ebi N, Hanagiri T, Tanaka F. Phase II trial of carboplatin/docetaxel in patients with resected NSCLC. World J Respirol 2014; 4(1): 1-7
- URL: https://www.wjgnet.com/2218-6255/full/v4/i1/1.htm
- DOI: https://dx.doi.org/10.5320/wjr.v4.i1.1